Physicians' Academy for Cardiovascular Education

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Mutated bone marrow stem cells may link aging, cancer and atherosclerosis

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Rudolfstiftung Hospital, Vienna, Austria

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Appropriate use of NOACs: What is the state of the art for 2018?

15' education - Feb. 20, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK

Practical guidance on NOACs and safety: How to deal with challenging situations in AF

15' education - Feb. 20, 2018 - Prof. John Eikelboom - Hamilton, ON, Canada

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial

3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

A threefold role of cardiologists as advocates for better cardiology care

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA

Great interpersonal variation in estimated benefit from PCSK9 inhibition in CAD patients

Literature - Apr. 26, 2018 - Kaasenbrood L, et al. - Heart 2018

The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.

Pharmacotherapy assisted smoking cessation does not increase CV risk

Literature - Apr. 25, 2018 - Benowitz NL, et al. - JAMA Intern Med 2018

In the EAGLES trial, smoking cessation pharmacotherapy did not increase the risk of serious CV disease or CV AEs in a general population of smokers without a history of CV disease.

Pneumococcal and influenza infections associated with higher risk of CV events

Literature - Apr. 25, 2018 - Warren-Gash C, et al. - Eur Respir J 2018
Individuals with at least one laboratory-confirmed respiratory infection had a higher risk of MI or stroke, in particular when infected with S. pneumoniae or influenza virus.

Individuals with at least one laboratory-confirmed respiratory infection had a higher risk of MI or stroke, in particular when infected with S. pneumoniae or influenza virus.

Inflammatory response is activated in end stage HF: a potential new therapeutic target?

News - Apr. 24, 2018

A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.

Total cholesterol levels determine survival in homozygous FH

Literature - Apr. 24, 2018 - Thompson GR - Eur Heart J 2018
In a retrospective survey of 133 patients with HoFH, the total serum cholesterol achieved by lipid-lowering therapies, was a major determinant of survival.

In a retrospective survey of 133 patients with HoFH, the total serum cholesterol achieved by lipid-lowering therapies, was a major determinant of survival.

Physical activity may modify high genetic risk for CVD

Literature - Apr. 23, 2018 - Tikkanen E, et al. - Circulation 2018

Different measures of fitness and physical activity were inversely associated with future CVD events and all-cause death, also in individuals with a high genetic CVD predisposition.

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen
This conversation covers differences in efficacy and safety outcomes of treatment with DOACs or VKA, and how to decide what to give to whom and for how long, in light of the risk of antithrombotic and bleeding complications.

This conversation covers differences in efficacy and safety outcomes of treatment with DOACs or VKA, and how to decide what to give to whom and for how long, in light of the risk of antithrombotic and bleeding complications.

Meeting Impression | Latest frontiers in anticoagulation therapy

EBAC accredited session held on January 12, 2018
EBAC accredited session held on January 12, 2018

In this live webcast, recent clinical evidence on NOACs/DOACs in patients with both(AF and VTE were summarized.

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA
**ACC 2018** The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.

ACC 2018 The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.

Elevated pro-inflammatory biomarkers associated with decompensation in HFpEF

Literature - Apr. 18, 2018 - Abernethy A et al. - J Am Heart Assoc. 2018
Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.

Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.

Greater risk reduction with PCSK9 inhibition in readily ascertainable high risk patient subgroups

Literature - Apr. 18, 2018 - Sabatine MS et al. - Circulation. 2018
Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.

Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.

HFrEF patients can safely fast during Ramadan, but adherence to medication and diet is important

News - Apr. 17, 2018

Ramadan starts on May 16. A study found that religious fasting is safe for patients with HFrEF, but non-adherence to medication and diet increases the risk of decompensated HF.